The Geroscience IndexWho's who in the science of aging
← All labs

Altos Labs

Commercial

About

Altos Labs is a biotechnology company whose stated mission is to restore cell health and resilience through cell rejuvenation in order to reverse disease, injury and disability. It launched in January 2022, founded by Hal Barron, Rick Klausner and Hans Bishop, and combines academic-style principal-investigator groups with industrial drug development. Research is organised into Institutes of Science in the San Francisco Bay Area, San Diego and Cambridge (UK), an Institute of Medicine for translation, and a later-formed Institute of Computation building generative models of cell and organ health. Its scientists work on cellular rejuvenation programming, including partial epigenetic reprogramming, epigenetic ageing clocks, senescence and stem-cell ageing. In 2025 the company appointed Joan Mannick as Chief Medical Officer to lead clinical programmes within the Institute of Medicine.

Rating breakdown

Aggregate 36/100 · rank #11 in the commercial table full ratings →

Expand a signal to see what contributes to it.

Publications100
Discovery0

No geroprotective trials, assets or deals recorded.

Development0

No clinical-stage geroprotective trials recorded.

Fundraising75
  • 2022-01 — Altos Labs launch capital publicly reported as USD 3 billion (STAT and Fierce Biotech, January 2022) · USD 3.00B · ARCH Venture Partners source ↗
Education55

Key outputs

Registered clinical trials

1 trials list this organisation as lead sponsor ClinicalTrials.gov ↗

Financial

Financing rounds

DateAmountRoundInvestors
2022-01USD 3.00BAltos Labs launch capital publicly reported as USD 3 billion (STAT and Fierce Biotech, January 2022)ARCH Venture Partners

Key people

Research fields

Links

Sources